Merck: EXZOLT Win, Guidance Miss, Animal Push 2026

Introduction

Merck & Co. (MRK) drew investor attention this week after reporting mixed forward guidance while simultaneously advancing a material animal-health agenda. Concrete developments — a stock uptick, a guidance miss for 2025, regulatory progress for an animal parasiticide, and a multibillion-dollar production expansion — together create a clear, non‑speculative view of near‑term pressure and longer‑term optionality for the company.

Quarterly results and guidance: the numbers that mattered

Merck closed a recent session up roughly 2.5%, trading near its 52‑week high reached earlier in January. That bounce reflected investor focus on company fundamentals rather than broad market moves.

Earnings and profit outlook

For 2024 Merck reported adjusted earnings of about $7.65 per share — a beat on many metrics but slightly shy of the company’s internal guidance range. Looking to 2025, management issued revenue guidance of $64.1–$65.6 billion and an EPS range of $8.88–$9.03. Both figures came in under Street expectations (consensus revenue nearer to $68 billion and EPS around $9.18). Management flagged a roughly $0.35 per‑share currency headwind and a one‑time ~ $300 million milestone payment (~$0.09 per share) tied to a licensing transaction, both of which are baked into the outlook.

Concrete headwinds and tailwinds

Two measurable headwinds weighed on the forecast: a continued pause of Gardasil activity in China, and anticipated impacts from Medicare Part D redesign estimated around $400 million that primarily affect certain oncology and respiratory sales. On the upside, Merck cited continued momentum from Keytruda (notably in earlier‑stage indications), steady performance from recently launched products such as Welireg and Winrevair, and contribution from its animal‑health business.

Animal health: tangible wins and capacity investment

Unlike speculative headlines, the animal‑health developments are specific and immediately actionable for Merck’s long‑term revenue mix.

Regulatory approval: EXZOLT for cattle

The company secured conditional approval for EXZOLT CATTLE‑CA1, a topical isoxazoline pour‑on parasiticide for the prevention and treatment of screwworm in cattle. This is a regulatory milestone with a obvious commercial pathway: EXZOLT addresses a specific veterinary need and expands Merck’s product offering in livestock parasitology.

Manufacturing expansion in Kansas

Merck is executing a near‑term industrial expansion with an $8.95 billion commitment to its De Soto, Kansas campus focused on molecular vaccines and biologics for animal health. This is a capital‑heavy, multi‑year program expected to add significant production capacity and R&D capability — a tangible investment that supports commercialization of new biologics and scale for established products.

How these events influence MRK stock

The combination of a conservative near‑term financial outlook and decisive investments in animal health leads to a two‑tiered interpretation by investors. In the near term, missed revenue and EPS expectations can pressure valuation multiples and sentiment. But the animal health approvals and large-scale manufacturing investment provide a measurable growth vector that can support valuation over the medium term.

Think of Merck’s positioning like a diversified farm: some fields (core oncology and vaccines) may yield less this season due to weather and policy, while new orchards (animal biologics and parasiticides) are being planted now and will produce over multiple seasons. The company’s immediate guidance is conservative, but the strategic investments reduce single‑product dependency and add durable capacity.

Conclusion

Merck entered the week with clear, verifiable signals: a modest stock rally on favorable trading sentiment, a 2025 guidance package that missed consensus due to identifiable headwinds, and concrete animal‑health advances including EXZOLT approval and a nearly $9 billion production expansion. These are non‑speculative developments that map directly to MRK’s risk and opportunity profile: near‑term caution from product pauses and policy shifts, counterbalanced by tangible investments and regulatory wins that can underpin longer‑term growth.

Investors weighing Merck should separate transient policy and regional disruptions from the company’s execution on product development and manufacturing scale — both of which are demonstrable and already affecting financial guidance.